metastatic Clear Cell Renal Cell Carcinoma (ccRCC) (DBCOND0148457)

Identifiers

Synonyms
Metastatic Clear Cell Renal Cancer / Metastatic Clear-cell Renal Cancer / Clear Cell Renal Cell Carcinoma Metastatic / Clear Cell Metastatic Renal Cell Carcinoma / Metastatic Clear Cell Renal Cell Carcinoma / Metastatic Clear-Cell Renal Cell Carcinoma / Metastatic Clear Cell Renal Carcinoma / Clear Cell, Metastatic Renal Cell Carcinoma / Clear-cell Metastatic Renal Cell Carcinoma / Metastatic clear cell renal cell carcinoma (disorder) / Clear cell renal cell carcinoma (morphologic abnormality) / Hypernephroma / Renal cell carcinoma (morphologic abnormality) / Clear cell carcinoma of kidney (disorder) / Clear Cell Renal Cell Carcinoma / Renal clear cell carcinoma / Clear cell carcinoma of the kidney

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Cabozantinib
A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT01512186
A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)No drug interventionsNot AvailableNot Availableunknown_status
NCT01714765
Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancertreatment1completed
NCT02035358
Immunotherapy Study for Metastatic Renal Cell CancerNo drug interventionstreatment1completed
NCT05753839
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN TrialNo drug interventionstreatmentNot Availablerecruiting
NCT05698238
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid TumoursNo drug interventionstreatment1not_yet_recruiting
NCT06389682
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in PatientsNo drug interventionsdiagnostic1recruiting
NCT05363631
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumabtreatment1 / 2recruiting
NCT02019576
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With SunitinibNo drug interventionstreatment2completed
NCT02960906
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancertreatment2completed
NCT04904302
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancertreatment2active_not_recruiting
NCT04370509
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgerytreatment2recruiting
NCT05012371
Lenvatinib with Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancertreatment2active_not_recruiting
NCT06349642
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic PlatformNo drug interventionsNot AvailableNot Availablerecruiting
NCT02848768
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell CarcinomaNot AvailableNot Availablecompleted
NCT06361810
PSMA Therapy and Immunotherapy in Kidney Cancertreatment1 / 2not_yet_recruiting
NCT06059014
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancertreatment1 / 2recruiting
NCT06428708
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell CarcinomaNo drug interventionsdiagnostic0recruiting
NCT04510597
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialNo drug interventionstreatment3recruiting
NCT05879471
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell CarcinomaNo drug interventionsdiagnostic2recruiting
NCT01896271
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal CancerNo drug interventionstreatment2completed
NCT03334409
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgerytreatment2terminated
NCT04388852
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancerstreatment1recruiting
NCT02781506
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinomatreatment2terminated
NCT01510119
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinomatreatment1 / 2completed
NCT06399419
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancertreatment1recruiting
NCT01391130
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinomatreatment2terminated
NCT05361720
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Studytreatment2recruiting
NCT03260504
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancertreatment1terminated
NCT05122546
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancertreatment1active_not_recruiting
NCT02002312
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancertreatment2completed
NCT03679767
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)treatment2completed
NCT05782400
Multiomics Approach in Metastatic Clear Renal Cell CarcnomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT01793636
A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancertreatment2terminated
NCT01499121
Study of Efficacy and Safety of Sunitinib Given on an Individualized Scheduletreatment2completed
NCT05263050
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumorstreatment2recruiting
NCT06279403
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinomatreatment2not_yet_recruiting
NCT02228954
IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)No drug interventionsNot AvailableNot Availablecompleted
NCT02535351
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discoverytreatment3terminated
NCT05567588
Pembrolizumab Plus Radiotherapy for Advanced Renal Cancertreatment2recruiting
NCT05745142
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.Not AvailableNot Availablecompleted
NCT02724020
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinomatreatment2completed
NCT02917772
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinomatreatment2completed
NCT02880943
Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)treatment1 / 2unknown_status
NCT02543645
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancertreatment1terminated
NCT02386111
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinomatreatment1terminated
NCT01521715
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinomatreatment4completed
NCT01715935
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With EverolimusNot Available2completed
NCT01693822
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomytreatment2completed
NCT02570789
Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapybasic_science4terminated
NCT02978404
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastasestreatment2completed
NCT01472081
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)treatment1completed